We are currently experiencing degraded performance with our storage system. We greatly appreciate your patience and we apologize for the general slowness and any inconvenience. Click here to join our chat for updates.

CERN Accelerating science

Title Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617
Author(s) Umbricht, Christoph A. (PSI, Villigen) ; Gracheva, Nadezda (PSI, Villigen) ; Johnston, Karl (CERN) ; Schibli, Roger (PSI, Villigen ; Zurich, ETH) ; van der Meulen, Nicholas P. (PSI, Villigen) ; Müller, Cristina (PSI, Villigen ; ETH, Zurich) ; Bernhardt, Peter (Chalmers U. Tech.) ; Koster, Ulli (Laue-Langevin Inst.)
In: Sci. Rep. 9 (2019) 17800
DOI 10.1038/s41598-019-54150-w
Accelerator/Facility, Experiment CERN ISOLDE ; IS528
Abstract In this study, it was aimed to investigate$^{149}$Tb-PSMA-617 for targeted α-therapy (TAT) using a mouse model of prostate-specific membrane antigen (PSMA)-expressing prostate cancer.$^{149}$Tb-PSMA-617 was prepared with >98% radiochemical purity (6 MBq/nmol) for the treatment of mice with PSMA-positive PC-3 PIP tumors.$^{149}$Tb-PSMA-617 was applied at 1 × 6 MBq (Day 0) or 2 × 3 MBq (Day 0 & Day 1 or Day 0 & Day 3) and the mice were monitored over time until they had reached a pre-defined endpoint which required euthanasia. The tumor growth was significantly delayed in mice of the treated groups as compared to untreated controls (p < 0.05). TAT was most effective in mice injected with 2 × 3 MBq (Day 0 & 1) resulting in a median lifetime of 36 days, whereas in untreated mice, the median lifetime was only 20 days. Due to the β$^{+}$-emission of$^{149}$Tb, tumor localization was feasible using PET/CT after injection of$^{149}$Tb-PSMA-617 (5 MBq). The PET images confirmed the selective accumulation of$^{149}$Tb-PSMA-617 in PC-3 PIP tumor xenografts. The unique characteristics of$^{149}$Tb for TAT make this radionuclide of particular interest for future clinical translation, thereby, potentially enabling PET-based imaging to monitor the radioligand’s tissue distribution.
Copyright/License publication: © 2019-2020 The Authors (License: CC-BY-4.0)

Corresponding record in: Inspire
Email contact: karl.johnston@cern.ch

 Δημιουργία εγγραφής 2019-11-28, τελευταία τροποποίηση 2019-12-20

Πλήρες κείμενο:
Κατέβασμα πλήρες κειμένου